Anti-EBNA-1 IgG is not a reliable marker of multiple sclerosis clinical disease activity

European Journal of Neurology

Volumn 17, Issue 11, 2010, Pages 1386-1389

  Ingram, G ^a   Bugert, J J ^b   Loveless, S ^b   Robertson, N P ^a  

^a Departments of Neurosciences and Psychological medicine   (United Kingdom)

^b CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

Epstein barr virus; Multiple sclerosis; Prognosis; Viral infections

Indexed keywords

ANTI EPSTEIN BARR VIRUS NUCLEAR ANTIGEN 1 IMMUNOGLOBULIN G; ANTINUCLEAR ANTIBODY; BETA1A INTERFERON; BIOLOGICAL MARKER; EPSTEIN BARR VIRUS ANTIGEN 1; IMMUNOGLOBULIN G; STEROID; UNCLASSIFIED DRUG; VIRUS ANTIBODY;

ADULT; ANTIBODY BLOOD LEVEL; CONTROLLED STUDY; CORRELATION COEFFICIENT; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE COURSE; EDITORIAL; ENZYME LINKED IMMUNOSORBENT ASSAY; EPSTEIN BARR VIRUS INFECTION; FEMALE; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; QUANTITATIVE ANALYSIS; RELAPSE; RELIABILITY; REMISSION; SEROEPIDEMIOLOGY; VIRUS REACTIVATION;

ADULT; AGED; ANTIBODIES, VIRAL; BIOLOGICAL MARKERS; DISABILITY EVALUATION; DISEASE PROGRESSION; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPSTEIN-BARR VIRUS NUCLEAR ANTIGENS; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS;

EID: 78650455250     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/j.1468-1331.2010.03083.x     Document Type: Editorial

References (14)

1. Haahr S, Hollsberg P. Multiple sclerosis is linked to Epstein-Barr virus infection. Rev Med Virol 2006; 16: 297-310.
2. Bagert BA. Epstein-Barr virus in multiple sclerosis. Curr Neurol Neurosci Rep 2009; 9: 405-410.
3. Ascherio A, Munger KL, Lennette ET, et al. Epstein-Barr virus antibodies and risk of multiple sclerosis: a prospective study. JAMA 2001; 286: 3083-3088.
4. Sundstrom P, Juto P, Wadell G, et al. An altered immune response to Epstein-Barr virus in multiple sclerosis: a prospective study. Neurology 2004; 62: 2277-2282.
5. Sumaya CV, Myers LW, Ellison GW, Ench Y. Increased prevalence and titer of Epstein-Barr virus antibodies in patients with multiple sclerosis. Ann Neurol 1985; 17: 371-377.
6. Larsen PD, Bloomer LC, Bray PF. Epstein-Barr nuclear antigen and viral capsid antigen antibody titers in multiple sclerosis. Neurology 1985; 35: 435-438.
7. Buljevac D, Van Doornum GJ, Flach HZ, et al. Epstein-Barr virus and disease activity in multiple sclerosis. J Neurol Neurosurg Psychiatry 2005; 76: 1377-1381.
8. Torkildsen O, Nyland H, Myrmel H, Myhr KM. Epstein-Barr virus reactivation and multiple sclerosis. Eur J Neurol 2008; 15: 106-108.
9. Lindsey JW, Hatfield LM, Crawford MP, Patel S. Quantitative PCR for Epstein-Barr virus DNA and RNA in multiple sclerosis. Mult Scler 2009; 15: 153-158.
10. Farrell RA, Antony D, Wall GR, et al. Humoral immune response to EBV in multiple sclerosis is associated with disease activity on MRI. Neurology 2009; 73: 32-38.
11. Roxburgh RH, Seaman SR, Masterman T, et al. Multiple Sclerosis Severity Score: using disability and disease duration to rate disease severity. Neurology 2005; 64: 1144-1151.
12. Bray PF, Bloomer LC, Salmon VC, Bagley MH, Larsen PD. Epstein-Barr virus infection and antibody synthesis in patients with multiple sclerosis. Arch Neurol 1983; 40: 406-408.
13. Munch M, Riisom K, Christensen T, Moller-Larsen A, Haahr S. The significance of Epstein-Barr virus seropositivity in multiple sclerosis patients? Acta Neurol Scand 1998; 97: 171-174.
14. Bruu AL, Hjetland R, Holter E, et al. Evaluation of 12 commercial tests for detection of Epstein-Barr virus-specific and heterophile antibodies. Clin Diagn Lab Immunol 2000; 7: 451-456.